Paysign (PAYS) Q2 Revenue Jumps 33%
Paysign (NASDAQ:PAYS), a payment solutions provider specializing in healthcare and pharmaceutical programs, released its second quarter 2025 earnings results on August 5, 2025. Paysign reported GAAP revenue of $19.08 million, up 33.1% from the prior year and above analyst expectations of $18.69 million (GAAP). Net income (GAAP) reached $1.39 million, or $0.02 per diluted share. Adjusted EBITDA rose sharply to $4.51 million, up 101.8% year-over-year (non-GAAP, Adjusted EBITDA). The pharma patient affordability segment saw robust growth, with revenue increasing 189.9% year-over-year. but weakening trends in the plasma business. Overall, Paysign outpaced estimates on GAAP revenue and non-GAAP operating profit but is managing cost pressures and sector-specific challenges in some business lines.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Paysign provides prepaid card solutions serving the healthcare, pharmaceutical, and corporate sectors. Its platforms enable electronic payment processing, including tailored programs for plasma donor compensation and pharmaceutical patient affordability initiatives. By integrating advanced fintech tools, Paysign streamlines payments and offers detailed analytics for its clients.
Source Fool.com
